Hikma Pharmaceuticals (LON:HIK) had its price target boosted by equities researchers at Jefferies Group from GBX 1,045 ($13.99) to GBX 1,074 ($14.38) in a research report issued on Monday. The brokerage currently has a “hold” rating on the stock. Jefferies Group’s price objective points to a potential upside of 5.29% from the company’s previous close.
A number of other research analysts have also recently commented on the company. Morgan Stanley reissued an “equal weight” rating and issued a GBX 1,100 ($14.73) target price on shares of Hikma Pharmaceuticals in a research note on Friday. Peel Hunt reissued a “hold” rating and issued a GBX 1,390 ($18.62) target price on shares of Hikma Pharmaceuticals in a research note on Wednesday, November 15th. J P Morgan Chase & Co reduced their target price on Hikma Pharmaceuticals from GBX 1,250 ($16.74) to GBX 1,000 ($13.39) and set a “neutral” rating on the stock in a research note on Friday, November 10th. reduced their target price on Hikma Pharmaceuticals from GBX 1,060 ($14.20) to GBX 865 ($11.58) and set a “reduce” rating on the stock in a research note on Friday, November 10th. Finally, Stifel Nicolaus reduced their target price on Hikma Pharmaceuticals from GBX 1,320 ($17.68) to GBX 1,000 ($13.39) and set a “hold” rating on the stock in a research note on Thursday, November 9th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of GBX 1,188.90 ($15.92).
Hikma Pharmaceuticals (HIK) opened at GBX 1,020 ($13.66) on Monday. Hikma Pharmaceuticals has a 12 month low of GBX 906.50 ($12.14) and a 12 month high of GBX 2,346 ($31.42).
ILLEGAL ACTIVITY NOTICE: This news story was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2017/12/04/hikma-pharmaceuticals-hik-pt-raised-to-gbx-1074-at-jefferies-group.html.
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
What are top analysts saying about Hikma Pharmaceuticals PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Hikma Pharmaceuticals PLC and related companies.